- Home
- LYEL vs EARN Comparison
LYEL vs EARN Comparison
Compare LYEL & EARN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYEL
- EARN
- Stock Information
- Founded
- LYEL 2018
- EARN 2012
- Country
- LYEL United States
- EARN United States
- Employees
- LYEL N/A
- EARN N/A
- Industry
- LYEL Biotechnology: Pharmaceutical Preparations
- EARN Real Estate Investment Trusts
- Sector
- LYEL Health Care
- EARN Real Estate
- Exchange
- LYEL Nasdaq
- EARN Nasdaq
- Market Cap
- LYEL 207.7M
- EARN 187.6M
- IPO Year
- LYEL 2021
- EARN 2013
- Fundamental
- Price
- LYEL $0.44
- EARN $5.62
- Analyst Decision
- LYEL Sell
- EARN Buy
- Analyst Count
- LYEL 2
- EARN 2
- Target Price
- LYEL $1.00
- EARN $5.88
- AVG Volume (30 Days)
- LYEL 627.4K
- EARN 355.9K
- Earning Date
- LYEL 05-13-2025
- EARN 05-20-2025
- Dividend Yield
- LYEL N/A
- EARN 17.08%
- EPS Growth
- LYEL N/A
- EARN N/A
- EPS
- LYEL N/A
- EARN N/A
- Revenue
- LYEL $65,000.00
- EARN $34,563,000.00
- Revenue This Year
- LYEL N/A
- EARN N/A
- Revenue Next Year
- LYEL N/A
- EARN $16.66
- P/E Ratio
- LYEL N/A
- EARN N/A
- Revenue Growth
- LYEL N/A
- EARN 37.99
- 52 Week Low
- LYEL $0.39
- EARN $4.33
- 52 Week High
- LYEL $2.80
- EARN $7.20
- Technical
- Relative Strength Index (RSI)
- LYEL 51.63
- EARN 53.40
- Support Level
- LYEL $0.39
- EARN $5.33
- Resistance Level
- LYEL $0.43
- EARN $5.68
- Average True Range (ATR)
- LYEL 0.03
- EARN 0.12
- MACD
- LYEL 0.00
- EARN 0.01
- Stochastic Oscillator
- LYEL 83.39
- EARN 70.73
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About EARN Ellington Residential Mortgage REIT of Beneficial Interest
Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on strong risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times of stress. It also leverages Ellington's proprietary technology, analytics and risk management systems to enhance underwriting and investment selection and to guide ongoing portfolio monitoring and surveillance.